Related Experiment Video
Updated: Sep 9, 2025
A Model of Chronic Nutrient Infusion in the Rat
Published on: August 14, 2013
Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and
Arzu Kalayci1,2, James Louis Januzzi2,3, Makiko Mitsunami4
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Abstract:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D), but heterogeneity exists across cardiovascular outcome trials (CVOTs). A comprehensive search of PubMed, EMBASE, and Cochrane Library was conducted through November 2024. Eligible CVOTs compared GLP-1 RAs with placebo in T2D patients. The primary outcome was MACE, defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was assessed using I², τ², and R². Meta-regression analyses evaluated the influence of baseline covariates on cardiovascular benefits of GLP-1 RAs, contingent upon the detection of moderate to substantial heterogeneity (I² ≥ 30%). Sensitivity analyses and GRADE assessments were also performed. Ten trials (67 769 patients; 34 536 receiving GLP-1 RAs) were analyzed. GLP-1 RAs significantly reduced MACE compared with placebo (OR = 0.87, 95% CI: 0.81-0.93, P < 0.001, I² = 48.4%). Cardiovascular death (OR = 0.86, 95% CI: 0.79-0.94, P < 0.001, I² = 22.6%) and all-cause mortality (OR = 0.87, 95% CI: 0.82-0.94, P < 0.001, I² = 17.7%) were also reduced. Meta-regression revealed a greater cardiovascular benefit in patients with higher baseline body mass index (BMI; logOR = -0.098 per kg/m², P = 0.006, R² = 99.98%) and older age (logOR = -0.033 per year, P = 0.023, R² = 75.47%). Sensitivity analyses confirmed the robustness of these findings, with consistent effect sizes and no single trial unduly influencing the results. The certainty of evidence was rated as high for all outcomes based on GRADE criteria. GLP-1 RAs significantly reduce MACE, cardiovascular death, and all-cause mortality in T2D patients. Higher baseline BMI and older age were associated with greater cardiovascular benefit.
Insights
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly lower cardiovascular events and mortality in type 2 diabetes patients. Benefits were greater in individuals with higher baseline BMI and older age.
Area of Science:
- Cardiovascular Research
- Endocrinology
- Clinical Trials
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established treatments for type 2 diabetes (T2D).
- Previous cardiovascular outcome trials (CVOTs) demonstrated cardiovascular benefits of GLP-1 RAs, but with observed heterogeneity.
- Understanding factors influencing these benefits is crucial for optimizing patient care.
Purpose of the Study:
- To conduct a comprehensive meta-analysis of CVOTs to quantify the cardiovascular benefits of GLP-1 RAs in T2D patients.
- To investigate potential sources of heterogeneity and identify baseline covariates associated with differential cardiovascular risk reduction.
- To assess the impact of GLP-1 RAs on major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality.
Main Methods:
- A systematic literature search was performed across PubMed, EMBASE, and Cochrane Library up to November 2024.
- Ten eligible CVOTs involving 67,769 patients were included in the meta-analysis.
- Random-effects models were used to pool odds ratios (ORs) for MACE, cardiovascular death, and all-cause mortality, with heterogeneity assessed by I², τ², and R².
Main Results:
- GLP-1 RAs significantly reduced MACE (OR = 0.87, 95% CI: 0.81-0.93, P < 0.001, I² = 48.4%) compared to placebo.
- Significant reductions were also observed for cardiovascular death (OR = 0.86, 95% CI: 0.79-0.94, P < 0.001) and all-cause mortality (OR = 0.87, 95% CI: 0.82-0.94, P < 0.001).
- Meta-regression identified higher baseline body mass index (BMI) and older age as predictors of greater cardiovascular benefit.
Conclusions:
- GLP-1 RAs provide significant cardiovascular protection in patients with T2D, reducing MACE and mortality.
- The magnitude of cardiovascular benefit is influenced by baseline patient characteristics, particularly BMI and age.
- These findings support the use of GLP-1 RAs in T2D management, with potential for personalized risk reduction strategies.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:23Dipeptidyl Peptidase 4 Inhibitors
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
01:06Oral Hypoglycemic Agents: Glinides
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications